Study aid only. Verify against current NCCN, primary literature, AJCC/FIGO staging manuals, and prescribing information before clinical use.

About HemeOncBuddy

Team, terms, license, privacy, and contact.

Welcome

Research in hematology and oncology has seen remarkable growth over the last decade, and keeping up with the literature has only gotten harder. HemeOncBuddy is a focused reference for fellows and trainees: pivotal clinical trial summaries, interactive staging flashcards, and concise board-prep notes — all kept current from a single source of truth.

Every trial summary follows the same structure: background and inclusion criteria, study arms, primary and secondary endpoints, median follow-up, key efficacy results, and notable adverse events. Results are always reported in the same order — experimental arm first, control arm second — so once you learn the pattern you can scan summaries quickly. The database is updated on an ongoing basis from primary literature.

Team

HemeOncBuddy began during the first year of fellowship as a way to automate sharing of personal study notes. It grew into a collaborative project with contributions from many fellows and editors over the years. The site is currently maintained and actively edited by Veli Bakalov, MD, with ongoing contributions from a small group of clinical editors.

Active editors

Veli Bakalov, MD

Veli Bakalov, MD

Founder & Chief Editor
Hematology & Oncology · MD Anderson Cancer Center at Cooper University Health Care

Clinical and research interests in thoracic oncology and head & neck malignancies, with a particular focus on lung cancer screening and the application of AI-related technologies in oncology.

Author of all flashcards and board-preparation notes; primary curator of the trials database.

I built HemeOncBuddy to simplify learning and share my notes as I studied. I hope it's useful — feedback always welcome.
Thejus Jayakrishnan, MD

Thejus Jayakrishnan, MD

Editor · Clinical Trials
Gastrointestinal Oncology · Dana-Farber Cancer Institute · Harvard Medical School

GI medical oncologist focused on early-onset gastrointestinal malignancies, using multi-omic approaches to identify biomarkers for screening and therapy. Multiple ASCO Conquer Cancer Merit Award recipient. Works with the Young-Onset Colorectal Cancer Center at Dana-Farber.

Contributor to clinical trial summaries.

Thejus and I trained together as internal medicine co-residents at Allegheny General Hospital in Pittsburgh — one of the friends and colleagues whose feedback shaped this project from day one.

Pragnan Kancharla, MD

Pragnan Kancharla, MD

Editor · Clinical Trials
Hematology & Oncology · MedStar Franklin Square Medical Center · Baltimore, MD

Hematologist and medical oncologist with research interests across solid tumor oncology, cardio-oncology, and disparities in cancer outcomes. Practices within the MedStar Health system.

Contributor to clinical trial summaries.

Pragnan and I were heme/onc co-fellows at Allegheny Health Network in Pittsburgh — close colleague and friend, and one of the earliest sounding boards for the project.

Past contributors

The following colleagues contributed to HemeOncBuddy in earlier phases of the project. Their work is gratefully acknowledged.

Reviewers

Deep Shah, MD · Santhosh Sadashiv, MD

Contributors

Zaid Abdel Rahman, MD · Youssef Bouferraa, MD · Maroun Bou Zerdan, MD · Anusha Chidharla, MD · Patricia Disperati, MD · Moises Harari-Turquie, MD · Rimal Ilyas, MD · Joseph Liput, DO · Ramya Vasireddy, MD · Richard White, DO

IT support

Kubedin B

Common abbreviations

Used throughout trial summaries and notes.

OSoverall survival
PFSprogression-free survival
DFSdisease-free survival
TTPtime to progression
mFollow Upmedian follow up
RRresponse rate
CRcomplete response
PRpartial response
HRhazard ratio
CIconfidence interval
ECOGEastern Cooperative Oncology Group
RECISTResponse Evaluation Criteria in Solid Tumors
AEadverse events
vsArm A (experimental) vs Arm B (control)
yr / mo / wk / dyear / month / week / day
*preliminary results from conference, no PMID yet
**ongoing trial, no results yet

Terms and conditions

By using HemeOncBuddy you agree to the terms of use below. We may update them periodically.

HemeOncBuddy is for educational purposes only and is not a substitute for medical advice, clinical judgment, or medical decision-making. It does not replace independent reading of original articles or current national guidelines. It should not be used as a guide to diagnose or treat patients. All summaries reflect editors' independent interpretations of the source articles and may contain errors; the field changes quickly and human error is possible.

The site is provided "as is" without warranties of any kind, express or implied. HemeOncBuddy and its editors disclaim liability for damages arising from any information here. If you have or suspect a medical problem, contact a qualified healthcare professional or call 911.

License

Unless otherwise noted, all original content on HemeOncBuddy is released under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

To request permission to reproduce or redistribute material in another publication, please email the address below.

Privacy

HemeOncBuddy uses standard analytics that collect anonymous usage data (pages viewed, time on page, device type, operating system). This data cannot be used to identify individual users and is used only to improve the resource.

External links may direct you to third-party sites whose privacy policies are not under our control.

Contact

Questions, corrections, or feedback: hemeoncbuddy@gmail.com